Analysts See $-0.82 EPS for Check-Cap Ltd. (CHEK)

July 21, 2018 - By Michele Cranor

Check-Cap Ltd. (NASDAQ:CHEK) Logo

Analysts expect Check-Cap Ltd. (NASDAQ:CHEK) to report $-0.82 EPS on August, 9.They anticipate $1.22 EPS change or 59.80 % from last quarter’s $-2.04 EPS. After having $-1.26 EPS previously, Check-Cap Ltd.’s analysts see -34.92 % EPS growth. The stock decreased 1.07% or $0.04 during the last trading session, reaching $3.69. About 56,740 shares traded. Check-Cap Ltd. (NASDAQ:CHEK) has declined 82.42% since July 21, 2017 and is downtrending. It has underperformed by 94.99% the S&P500.

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers. The company has market cap of $19.54 million. The Company’s C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit that is designed to track the capsule and record imaging and positioning data; and C-Scan View, a personal computer software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface. It currently has negative earnings.

Check-Cap Ltd. (NASDAQ:CHEK) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.